-
Something wrong with this record ?
Is high dose of Huperzine A really suitable for pretreatment of higher dose of soman: exists some reason for consideration?
Jana Zdarova Karasova, Jiri Bajgar, Ladislav Novotny, Kamil Kuca
Language English Country Czech Republic
Document type Chart
NLK
Free Medical Journals
from 2003 to 2013
Freely Accessible Science Journals
from 2003 to 2013
ROAD: Directory of Open Access Scholarly Resources
from 2002
- MeSH
- Acetylcholinesterase metabolism drug effects MeSH
- Animal Experimentation MeSH
- Financing, Organized MeSH
- Huperzia adverse effects toxicity MeSH
- Organophosphates adverse effects toxicity MeSH
- Rats, Wistar MeSH
- Sesquiterpenes administration & dosage adverse effects therapeutic use MeSH
- Soman analogs & derivatives adverse effects toxicity MeSH
- Spectrophotometry methods instrumentation utilization MeSH
- Statistics as Topic MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Animals MeSH
- Publication type
- Chart MeSH
Huperzine A (Hup A) is a reversible AChE inhibitor that crosses the blood-brain barrier. It is presently approved for, or is in a course of clinical trials for, the treatment of Alzheimer's disease. This compound has also been successfully tested for the pretreatment of organophosphate poisoning. Organophosphate nerve agents are potent irreversible inhibitors of acetylcholinesterase in the central and also in the peripheral compartment. In this study Hup A in a higher dose (500 micro g/kg) was tested as a prophylaxis against a high, mainly centrally acting, nerve agent (soman). According to the results obtained, Hup A in this dosage was not able to protect AChE against soman in both the peripheral and central compartments. The effect of Hup A and soman was found to be additive and all animal subjects died.
References provided by Crossref.org
Lit.: 25
- 000
- 00000naa 2200000 a 4500
- 001
- bmc09002341
- 003
- CZ-PrNML
- 005
- 20111210152431.0
- 008
- 091105s2009 xr e eng||
- 009
- AR
- 024 7_
- $a 10.32725/jab.2009.009 $2 doi
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Žďárová Karasová, Jana, $d 1982- $7 xx0099787
- 245 10
- $a Is high dose of Huperzine A really suitable for pretreatment of higher dose of soman: exists some reason for consideration? / $c Jana Zdarova Karasova, Jiri Bajgar, Ladislav Novotny, Kamil Kuca
- 314 __
- $a Faculty of Military Health Sciences, Department of Toxicology, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
- 504 __
- $a Lit.: 25
- 520 9_
- $a Huperzine A (Hup A) is a reversible AChE inhibitor that crosses the blood-brain barrier. It is presently approved for, or is in a course of clinical trials for, the treatment of Alzheimer's disease. This compound has also been successfully tested for the pretreatment of organophosphate poisoning. Organophosphate nerve agents are potent irreversible inhibitors of acetylcholinesterase in the central and also in the peripheral compartment. In this study Hup A in a higher dose (500 micro g/kg) was tested as a prophylaxis against a high, mainly centrally acting, nerve agent (soman). According to the results obtained, Hup A in this dosage was not able to protect AChE against soman in both the peripheral and central compartments. The effect of Hup A and soman was found to be additive and all animal subjects died.
- 650 _2
- $a seskviterpeny $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D012717
- 650 _2
- $a Huperzia $x škodlivé účinky $x toxicita $7 D032501
- 650 _2
- $a organofosfáty $x škodlivé účinky $x toxicita $7 D010755
- 650 _2
- $a soman $x analogy a deriváty $x škodlivé účinky $x toxicita $7 D012999
- 650 _2
- $a acetylcholinesterasa $x metabolismus $x účinky léků $7 D000110
- 650 _2
- $a experimenty na zvířatech $7 D032761
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a spektrofotometrie $x metody $x přístrojové vybavení $x využití $7 D013053
- 650 _2
- $a statistika jako téma $7 D013223
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a financování organizované $7 D005381
- 655 _2
- $a grafy a diagramy $7 D020468
- 700 1_
- $a Bajgar, Jiří, $d 1944- $7 js20020122033
- 700 1_
- $a Novotný, Ladislav, $d 1976- $7 xx0022121
- 700 1_
- $a Kuča, Kamil, $d 1978- $7 xx0041831
- 773 0_
- $w MED00012667 $t Journal of applied biomedicine $g Roč. 7, č. 2 (2009), s. 93-99 $x 1214-021X
- 856 41
- $u https://jab.zsf.jcu.cz/pdfs/jab/2009/02/03.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b B 2301 $c 1249 $y 8
- 990 __
- $a 20091105101214 $b ABA008
- 991 __
- $a 20110222093226 $b ABA008
- 999 __
- $a ok $b bmc $g 691512 $s 553411
- BAS __
- $a 3
- BMC __
- $a 2009 $b 7 $c 2 $d 93-99 $i 1214-021X $m Journal of Applied Biomedicine $x MED00012667
- LZP __
- $a 2009-59/vtal
